That is because each of these accounts is a network (closed or public) that handles hundreds to thousands of doctors writing prescriptions. Doctors are not accounts.
Was well into the market?
How many versions of generic renvela are actually available for sale in the EU, and from which manufacturers?
Your point is not relevant to the fact that an entity cannot get administrative approval by talking up recent clinical results, but rather solely through a formal and highly technical application process.
Maybe because a pharma cannot expand a label by taking up a clinical trial, but rather solely through the formal application process. The same question could have been asked about the US...why not talk it up to the FDA? Oh yeah, because that is asinine and could be harmful to the actual application process.
Why would they file for bankruptcy? They will not any time soon.
Are you alleging that they cannot pay their bills? They have no debt.
Their margins are on an average of 3,000 sales per month, with roughly 20% quarterly growth expected over the next 3 quarters, or roughly 5,200 sales per quarter in Q4 of this year. And that is before you consider the EU sales as well as a possible partnership.
I believe the positive move is based upon a realization that the company is losing money due to growing pains, but that the underlying product is selling at a very high margin. As adoption continues to ramp up, that will be a nice factor. The stock has no business being priced this low, even if the revenue number is not where we would like it to be. It will soon be there.
the margins will become more meaningful as adoption ramps, and volume might even improve the margins, which will be intense.
yeah, I saw that too, so as the costs of the NDA and ramp die down, the margin should be incredible and irresistible to big cap pharma.
whatever happened to the google doc spreadsheet/chart that someone was compiling of the weekly data? I think we should keep that going and if it isn't still active, I would try to update a new version it if anyone has the link to it.
you should factor half the probable effect of a day change, as on average about half of the business will be pushed forward, and about half will get pulled into the shortened week. The trend will continue for a while, likely doubling scrips every 4-5 months.
No, because this is not snake oil or some random commercial product at the drug store. This is a pharmaceutical drug that is highly regulated, and it is dangerous to tout anything prior to being given consent to do so. Similarly, if the CFO already knows that the first two months of Q1 were better/worse than expected, they simply cannot say so at this time. This is called professionalism.